Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Since we are already long or I am suggesting a long position in the primary indices which takes care of most of the largecaps, we are looking at smallcaps. There are plenty of opportunities. So starting with Ashok Leyland where the capital goods sector now seems to be gaining momentum, thanks to a lot of news flow, and that is reflecting in stock price chart, Ashok Leyland is a buy."
He further added, "Britannia Industries from the FMCG group is a buying opportunity and so is Divis Laboratories from the pharmaceutical sector. Almost all sectors are going to do well; I would have preferred private banks, but private banks are taken care of by the Nifty Bank itself. So these are midcaps otherwise."
"Biocon is probably going to be an outperformer among the pharmaceutical sector stocks. I am very upbeat on the stock. It is more of an investment buy rather than a short term trade," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!